The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Discovery of β-Arrestin–Biased Dopamine D 2 Ligands for Probing Signal Transduction Pathways Essential for Antipsychotic Efficacy
Open accessAbstract
Elucidating the key signal transduction pathways essential for both antipsychotic efficacy and side-effect profiles is essential for developing safer and more effective therapies. Recent work has highlighted noncanonical modes of dopamine D 2 receptor (D 2 R) signaling via β-arrestins as being important for the therapeutic actions of both antipsychotic and antimanic agents. We thus sought to create unique D 2 R agonists that display signaling bias via β-arrestin–ergic signaling. Through a robust diversity-oriented modification of the scaffold represented by aripiprazole (1), we discovered UNC9975 (2), UNC0006 (3), and UNC9994 (4) as unprecedented β-arrestin–biased D 2 R ligands. These compounds also represent unprecedented β-arrestin–biased ligands for a G i -coupled G protein–coupled receptor (GPCR). Significantly, UNC9975, UNC0006, and UNC9994 are simultaneously antagonists of G i -regulated cAMP production and partial agonists for D 2 R/β-arrestin-2 interactions. Importantly, UNC9975 displayed potent antipsychotic-like activity without inducing motoric side effects in inbred C57BL/6 mice in vivo. Genetic deletion of β-arrestin-2 simultaneously attenuated the antipsychotic actions of UNC9975 and transformed it into a typical antipsychotic drug with a high propensity to induce catalepsy. Similarly, the antipsychotic-like activity displayed by UNC9994, an extremely β-arrestin–biased D 2 R agonist, in wild-type mice was completely abolished in β-arrestin-2 knockout mice. Taken together, our results suggest that β-arrestin signaling and recruitment can be simultaneously a significant contributor to antipsychotic efficacy and protective against motoric side effects. These functionally selective, β-arrestin–biased D 2 R ligands represent valuable chemical probes for further investigations of D 2 R signaling in health and disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ferguson, S. S. G. (2001) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01478-9 · Cited by 1,826
Transduction of Receptor Signals by ß-Arrestins
Lefkowitz, R. J., & Shenoy, S. K. (2005) · Science · doi:10.1126/science.1109237 · Cited by 1,727
β-Arrestin-Dependent Formation of β 2 Adrenergic Receptor-Src Protein Kinase Complexes
Luttrell, L. M., Ferguson, S. S. G., Daaka, Y., Miller, W. E., Maudsley, S., Della Rocca, G. J., Lin, F.-T., Kawakatsu, H., Owada, K., Luttrell, D. K., et al. (1999) · Science · doi:10.1126/science.283.5402.655 · Cited by 1,475
Self-citationRoth, B. L., Sheffler, D. J., & Kroeze, W. K. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1346 · Cited by 1,155
Self-citationFunctional Selectivity and Classical Concepts of Quantitative Pharmacology
Urban, J. D., Clarke, W. P., von Zastrow, M., Nichols, D. E., Kobilka, B., Weinstein, H., Javitch, J. A., Roth, B. L., Christopoulos, A., Sexton, P. M., et al. (2007) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.104463 · Cited by 1,116
Self-citationEnhanced Morphine Analgesia in Mice Lacking β-Arrestin 2
Bohn, L. M., Lefkowitz, R. J., Gainetdinov, R. R., Peppel, K., Caron, M. G., & Lin, F.-T. (1999) · Science · doi:10.1126/science.286.5449.2495 · Cited by 1,077
Self-citationAn Akt/β-Arrestin 2/PP2A Signaling Complex Mediates Dopaminergic Neurotransmission and Behavior
Beaulieu, J.-M., Sotnikova, T. D., Marion, S., Lefkowitz, R. J., Gainetdinov, R. R., & Caron, M. G. (2005) · Cell · doi:10.1016/j.cell.2005.05.012 · Cited by 980
Self-citationAripiprazole, A Novel Atypical Antipsychotic Drug with a Unique and Robust Pharmacology
Shapiro, D. A., Renock, S., Arrington, E., Chiodo, L. A., Liu, L.-X., Sibley, D. R., Roth, B. L., & Mailman, R. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300203 · Cited by 968
Self-citationThe genetic design of signaling cascades to record receptor activation
Barnea, G., Strapps, W., Herrada, G., Berman, Y., Ong, J., Kloss, B., Axel, R., & Lee, K. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0710487105 · Cited by 678
The Role of Serotonin in Antipsychotic Drug Action
Meltzer, H. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(99)00046-9 · Cited by 662
β-Arrestin-biased ligands at seven-transmembrane receptors
Violin, J. D., & Lefkowitz, R. J. (2007) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2007.06.006 · Cited by 606
Akt/GSK3 Signaling in the Action of Psychotropic Drugs
Beaulieu, J.-M., Gainetdinov, R. R., & Caron, M. G. (2009) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.011008.145634 · Cited by 522
Self-citationLawler, C. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(98)00099-2 · Cited by 408
A β-arrestin 2 Signaling Complex Mediates Lithium Action on Behavior
Beaulieu, J.-M., Marion, S., Rodriguiz, R. M., Medvedev, I. O., Sotnikova, T. D., Ghisi, V., Wetsel, W. C., Lefkowitz, R. J., Gainetdinov, R. R., & Caron, M. G. (2008) · Cell · doi:10.1016/j.cell.2007.11.041 · Cited by 362
Self-citationEvidence that LY-141865 specifically stimulates the D-2 dopamine receptor
Tsuruta, K., Frey, E. A., Grewe, C. W., Cote, T. E., Eskay, R. L., & Kebabian, J. W. (1981) · Nature · doi:10.1038/292463a0 · Cited by 343
Masri, B., Salahpour, A., Didriksen, M., Ghisi, V., Beaulieu, J.-M., Gainetdinov, R. R., & Caron, M. G. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0803522105 · Cited by 320
Self-citationThird Generation Antipsychotic Drugs: Partial Agonism or Receptor Functional Selectivity?
Mailman, R., & Murthy, V. (2010) · Current Pharmaceutical Design · doi:10.2174/138161210790361461 · Cited by 311
Kikuchi, T., Tottori, K., Uwahodo, Y., Hirose, T., Miwa, T., Oshiro, Y., & Morita, S. (1995) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)10600-9 · Cited by 276
General Pharmacology of Clozapine
Coward, D. M. (1992) · British Journal of Psychiatry · doi:10.1192/s0007125000296840 · Cited by 239
Strategies to Discover Unexpected Targets for Drugs Active at G Protein–Coupled Receptors
Allen, J. A., & Roth, B. L. (2011) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010510-100553 · Cited by 216
Self-citationGPCR functional selectivity has therapeutic impact
Mailman, R. B. (2007) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2007.06.002 · Cited by 208
Gesty-Palmer, D., Flannery, P., Yuan, L., Corsino, L., Spurney, R., Lefkowitz, R. J., & Luttrell, L. M. (2009) · Science Translational Medicine · doi:10.1126/scitranslmed.3000071 · Cited by 205
Aripiprazole has Functionally Selective Actions at Dopamine D2 Receptor-Mediated Signaling Pathways
Urban, J. D., Vargas, G. A., von Zastrow, M., & Mailman, R. B. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301071 · Cited by 197
The pipeline and future of drug development in schizophrenia
Gray, J. A., & Roth, B. L. (2007) · Molecular Psychiatry · doi:10.1038/sj.mp.4002062 · Cited by 184
Self-citationChipkin, R. E., Iorio, L. C., Coffin, V. L., McQuade, R. D., Berger, J. G., & Barnett, A. (1988) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)13263-1 · Cited by 182
PSD-95 Is Essential for Hallucinogen and Atypical Antipsychotic Drug Actions at Serotonin Receptors
Abbas, A. I., Yadav, P. N., Yao, W.-D., Arbuckle, M. I., Grant, S. G. N., Caron, M. G., & Roth, B. L. (2009) · Journal of Neuroscience · doi:10.1523/jneurosci.1090-09.2009 · Cited by 145
Self-citationOshiro, Y., Sato, S., Kurahashi, N., Tanaka, T., Kikuchi, T., Tottori, K., Uwahodo, Y., & Nishi, T. (1998) · Journal of Medicinal Chemistry · doi:10.1021/jm940608g · Cited by 143
Rinaldi, M. L., Congy, C., Santucci, V., Simiand, J., Gautret, B., Neliat, G., Labeeuw, B., Fur, G. L., Soubrié, P., & Brelière, J. C. (1992) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)10821-5 · Cited by 116
Inoue, T., Domae, M., Yamada, K., & Furukawa, T. (1996) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)12799-7 · Cited by 92
Conn, P. J., & Roth, B. L. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301638 · Cited by 90
Self-citationImpact of D2 Receptor Internalization on Binding Affinity of Neuroimaging Radiotracers
Guo, N., Guo, W. X., Králíková, M., Jiang, M., Schieren, I., Narendran, R., Slifstein, M., Abi‐Dargham, A., Laruelle, M. A., Javitch, J. A., et al. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2009.189 · Cited by 85
Self-citationKilts, J. D., Connery, H. S., Arrington, E. G., Lewis, M. M., Lawler, C. P., Oxford, G. S., O’Malley, K. L., Todd, R. D., Blake, B. L., Nichols, D. E., et al. (2002) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.301.3.1179 · Cited by 83
Granger, B., & Albu, S. (2005) · Annals of Clinical Psychiatry · doi:10.1080/10401230591002048 · Cited by 82
Kimple, A. J., Soundararajan, M., Hutsell, S. Q., Roos, A. K., Urban, D. J., Setola, V., Temple, B. R. S., Roth, B. L., Knapp, S., Willard, F. S., et al. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.024711 · Cited by 80
Self-citationKlewe, I. V., Nielsen, S. M., TARPO, L., Urizar, E. T., Dipace, C., Javitch, J. A., Gether, U., Egebjerg, J., & Christensen, K. V. (2008) · Neuropharmacology · doi:10.1016/j.neuropharm.2008.03.015 · Cited by 77
Self-citationNordquist, R. E., Risterucci, C., Moreau, J., von Kienlin, M., Künnecke, B., Maco, M., Freichel, C., Riemer, C., & Spooren, W. P. J. M. (2007) · Neuropharmacology · doi:10.1016/j.neuropharm.2007.10.010 · Cited by 68
The Presynaptic Component of the Serotonergic System is Required for Clozapine's Efficacy
Yadav, P. N., Abbas, A. I., Farrell, M. S., Setola, V., Sciaky, N., Huang, X., Kroeze, W. K., Crawford, L. K., Piel, D., Keiser, M. J., et al. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2010.195 · Cited by 65
Self-citationCharacterizing Cannabinoid CB2 Receptor Ligands Using DiscoveRx PathHunter™ β-Arrestin Assay
McGuinness, D., Malikzay, A., Visconti, R. J., Lin, K., BAYNE, M. L., Monsma, F. J., & Lunn, C. A. (2009) · SLAS DISCOVERY · doi:10.1177/1087057108327329 · Cited by 60
Schlumberger, C., Pietraszek, M., Gravius, A., Klein, K.-U., Greco, S., Morè, L., & Danysz, W. (2009) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.09.006 · Cited by 48
Strachan, R. T., Sciaky, N., Cronan, M. R., Kroeze, W. K., & Roth, B. L. (2009) · Molecular Pharmacology · doi:10.1124/mol.109.061440 · Cited by 34
Self-citationAbbas, A. I., & Roth, B. L. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711335105 · Cited by 33
Self-citationJohnson, D. S., Choi, C., Fay, L. K., Favor, D. A., Repine, J. T., White, A. D., Akunne, H. C., Fitzgerald, L. W., Nicholls, K., Snyder, B. J., et al. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.01.059 · Cited by 24
Cited by
Roth, B. L. (2016) · Neuron · doi:10.1016/j.neuron.2016.01.040 · Cited by 1,742
Self-citationUltra-large library docking for discovering new chemotypes
Lyu, J., Wang, S., Balius, T. E., Singh, I., Levit, A., Moroz, Y. S., O’Meara, M. J., Che, T., Algaa, E., Tolmachova, K., et al. (2019) · Nature · doi:10.1038/s41586-019-0917-9 · Cited by 998
Self-citationAdenosine receptors as drug targets — what are the challenges?
Chen, J.-F., Eltzschig, H. K., & Fredholm, B. B. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3955 · Cited by 895
PRESTO-Tango as an open-source resource for interrogation of the druggable human GPCRome
Kroeze, W. K., Sassano, M. F., Huang, X.-P., Lansu, K., McCorvy, J. D., Giguère, P. M., Sciaky, N., & Roth, B. L. (2015) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.3014 · Cited by 755
Self-citationBiased signalling: from simple switches to allosteric microprocessors
Smith, J. S., Lefkowitz, R. J., & Rajagopal, S. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.229 · Cited by 738
Metadata
- Authors
- Allen, J. A., Yost, J. M., Setola, V., Chen, X., Sassano, M. F., Chen, M., Peterson, S., Yadav, P. N., Huang, X.-P., Feng, B., Jensen, N. H., Che, X., Bai, X., Frye, S. V., Wetsel, W. C., Caron, M. G., Javitch, J. A., Roth, B. L., & Jin, J.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2011-10-24
- Volume
- 108
- Issue
- 45
- Pages
- 18488-18493
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2082956345
- Cited by
- 350
- References
- 42
- FWCI
- 10.23
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.